Evidence map›Paper›PMID 34181413›Full record

ArticleMolecular pharmaceutics2021

Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization.

Cristina Prieto, Zoran Evtoski, María Pardo-Figuerez, Julia Hrakovsky, Jose M Lagaron

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cristina PrietoNovel Materials and Nanotechnology Group, Institute of Agrochemistry and Food Technology (IATA), Spanish Council for Scientific Research (CSIC), Calle Catedrático Agustín Escardino Benlloch 7, 46980 Paterna, Valencia, Spain.ORCID 0000-0002-0925-896X
Zoran EvtoskiNovel Materials and Nanotechnology Group, Institute of Agrochemistry and Food Technology (IATA), Spanish Council for Scientific Research (CSIC), Calle Catedrático Agustín Escardino Benlloch 7, 46980 Paterna, Valencia, Spain.
María Pardo-FiguerezNovel Materials and Nanotechnology Group, Institute of Agrochemistry and Food Technology (IATA), Spanish Council for Scientific Research (CSIC), Calle Catedrático Agustín Escardino Benlloch 7, 46980 Paterna, Valencia, Spain.
Julia HrakovskyR&D Finished Dosage Forms, Zakłady Farmaceutyczne Polpharma SA, ul. Pelplińska 19, 83-200 Starogard Gdański, Poland.
Jose M LagaronNovel Materials and Nanotechnology Group, Institute of Agrochemistry and Food Technology (IATA), Spanish Council for Scientific Research (CSIC), Calle Catedrático Agustín Escardino Benlloch 7, 46980 Paterna, Valencia, Spain.ORCID 0000-0002-0502-359X
Instituto de Agroquímica y Tecnología de Alimentos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-throughput drying and encapsulation technique called electrospraying assisted by pressurized gas (EAPG) was used for the first time to produce nanostructured valsartan within microparticles of excipients. Valsartan, a poorly absorbed and lipid-soluble drug, was selected since it is considered a good model for BCS class II drugs. Two different polymeric matrices were selected as excipients, i.e., hydroxypropyl methylcellulose (HPMC) and lactose monohydrate, while Span 20 was used as a surfactant. The produced 80% valsartan loading formulations were characterized in terms of morphology, crystallinity,

Indexed as

TemperatureAntihypertensive AgentsBiological AvailabilityCaco-2 CellsChemistry, PharmaceuticalCrystallizationDrug CarriersDrug CompoundingDrug LiberationExcipientsHexosesHumansHypromellose DerivativesNanoparticlesParticle SizeSolubilityAntihypertensive AgentsDrug CarriersExcipientsHexosesHypromellose Derivativessorbitan monolaurateSurface-Active AgentsValsartanBCS II drugenhanced bioavailabilityHPMClactose monohydratenanonizationvalsartan

Identifiers

PMID34181413
PMCPMC8494385
OpenAlexW3174089485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.